| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Circadian Rhythm | 71 | 2015 | 218 | 7.030 |
Why?
|
| Neoplasms | 38 | 2023 | 1667 | 2.820 |
Why?
|
| Breast Neoplasms | 45 | 2020 | 1536 | 2.780 |
Why?
|
| Antineoplastic Agents | 35 | 2021 | 1070 | 2.280 |
Why?
|
| Mammary Neoplasms, Experimental | 8 | 2010 | 114 | 1.730 |
Why?
|
| Period Circadian Proteins | 8 | 2009 | 16 | 1.640 |
Why?
|
| Menstrual Cycle | 13 | 2001 | 64 | 1.390 |
Why?
|
| Cell Cycle Proteins | 6 | 2009 | 230 | 1.200 |
Why?
|
| Cell Proliferation | 9 | 2015 | 1174 | 1.030 |
Why?
|
| Anemia | 7 | 2021 | 104 | 1.000 |
Why?
|
| Neovascularization, Pathologic | 7 | 2009 | 183 | 0.990 |
Why?
|
| Seasons | 6 | 2010 | 129 | 0.980 |
Why?
|
| Fluorouracil | 14 | 2008 | 130 | 0.970 |
Why?
|
| Chronotherapy | 6 | 2009 | 6 | 0.940 |
Why?
|
| Nuclear Proteins | 5 | 2008 | 271 | 0.920 |
Why?
|
| Floxuridine | 15 | 1995 | 20 | 0.920 |
Why?
|
| Cisplatin | 22 | 2004 | 192 | 0.890 |
Why?
|
| Mammary Neoplasms, Animal | 4 | 2009 | 44 | 0.890 |
Why?
|
| Female | 135 | 2020 | 38074 | 0.880 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2010 | 756 | 0.870 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2020 | 446 | 0.870 |
Why?
|
| Estrous Cycle | 4 | 2009 | 23 | 0.870 |
Why?
|
| Doxorubicin | 19 | 2009 | 231 | 0.860 |
Why?
|
| Drug Approval | 3 | 2020 | 50 | 0.850 |
Why?
|
| Humans | 160 | 2023 | 68618 | 0.840 |
Why?
|
| Animals | 86 | 2016 | 20881 | 0.810 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2008 | 468 | 0.790 |
Why?
|
| Transcription Factors | 5 | 2009 | 753 | 0.780 |
Why?
|
| Hematinics | 5 | 2020 | 52 | 0.780 |
Why?
|
| Mice | 48 | 2010 | 8474 | 0.740 |
Why?
|
| Quality of Life | 5 | 2016 | 1515 | 0.740 |
Why?
|
| beta Catenin | 3 | 2009 | 73 | 0.720 |
Why?
|
| Intestinal Mucosa | 5 | 2008 | 219 | 0.720 |
Why?
|
| Lung Neoplasms | 14 | 2017 | 1173 | 0.710 |
Why?
|
| Light | 5 | 2010 | 152 | 0.690 |
Why?
|
| Neoplasm Metastasis | 16 | 2007 | 306 | 0.690 |
Why?
|
| Medical Oncology | 4 | 2020 | 110 | 0.640 |
Why?
|
| Biosimilar Pharmaceuticals | 4 | 2021 | 25 | 0.640 |
Why?
|
| Clinical Trials as Topic | 6 | 2016 | 848 | 0.620 |
Why?
|
| Chronobiology Disorders | 4 | 2010 | 5 | 0.620 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2015 | 300 | 0.590 |
Why?
|
| Survival Rate | 6 | 2016 | 1056 | 0.590 |
Why?
|
| Estrus | 8 | 2007 | 14 | 0.590 |
Why?
|
| Mammography | 7 | 2008 | 310 | 0.590 |
Why?
|
| Biomarkers, Tumor | 3 | 2010 | 508 | 0.580 |
Why?
|
| Ovarian Neoplasms | 10 | 2006 | 267 | 0.570 |
Why?
|
| Sleep Wake Disorders | 2 | 2010 | 94 | 0.560 |
Why?
|
| Neutropenia | 2 | 2019 | 72 | 0.560 |
Why?
|
| Mastectomy | 8 | 2020 | 57 | 0.560 |
Why?
|
| Erythropoietin | 9 | 2020 | 96 | 0.550 |
Why?
|
| Mass Screening | 7 | 2006 | 843 | 0.550 |
Why?
|
| Melatonin | 5 | 2010 | 39 | 0.550 |
Why?
|
| Time Factors | 30 | 2016 | 4655 | 0.540 |
Why?
|
| Mice, Inbred C3H | 10 | 2010 | 134 | 0.530 |
Why?
|
| Kidney Neoplasms | 12 | 1995 | 206 | 0.530 |
Why?
|
| Infusion Pumps | 12 | 1996 | 39 | 0.500 |
Why?
|
| Papillomaviridae | 2 | 2005 | 104 | 0.490 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2015 | 268 | 0.470 |
Why?
|
| Carcinoma, Renal Cell | 8 | 1995 | 110 | 0.460 |
Why?
|
| Cytokines | 2 | 2009 | 866 | 0.450 |
Why?
|
| Biomarkers | 3 | 2016 | 1593 | 0.440 |
Why?
|
| Breast | 2 | 2007 | 137 | 0.440 |
Why?
|
| Middle Aged | 49 | 2020 | 21147 | 0.440 |
Why?
|
| Papillomavirus Infections | 2 | 2005 | 194 | 0.430 |
Why?
|
| Cell Division | 7 | 2009 | 541 | 0.420 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2009 | 219 | 0.420 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2012 | 74 | 0.400 |
Why?
|
| Darkness | 2 | 2010 | 27 | 0.400 |
Why?
|
| Genes, APC | 2 | 2008 | 15 | 0.390 |
Why?
|
| United States Food and Drug Administration | 4 | 2020 | 131 | 0.390 |
Why?
|
| Peer Group | 1 | 2012 | 104 | 0.390 |
Why?
|
| Hematopoiesis | 2 | 2015 | 108 | 0.390 |
Why?
|
| Adult | 46 | 2020 | 21403 | 0.390 |
Why?
|
| Menstruation | 2 | 2005 | 20 | 0.390 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2000 | 77 | 0.390 |
Why?
|
| Solar Activity | 1 | 2011 | 1 | 0.390 |
Why?
|
| Periodicity | 4 | 2011 | 43 | 0.380 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2020 | 129 | 0.380 |
Why?
|
| Aged | 40 | 2021 | 14862 | 0.370 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 498 | 0.370 |
Why?
|
| Down-Regulation | 5 | 2009 | 447 | 0.370 |
Why?
|
| Disease-Free Survival | 8 | 2020 | 349 | 0.360 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 66 | 0.360 |
Why?
|
| Male | 69 | 2020 | 37321 | 0.360 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2008 | 26 | 0.360 |
Why?
|
| Cell Line, Tumor | 6 | 2009 | 1851 | 0.360 |
Why?
|
| Neoplasms, Experimental | 11 | 2002 | 118 | 0.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2009 | 626 | 0.350 |
Why?
|
| G2 Phase | 1 | 2009 | 26 | 0.350 |
Why?
|
| Premenopause | 6 | 2007 | 57 | 0.350 |
Why?
|
| Colonic Neoplasms | 3 | 2009 | 299 | 0.350 |
Why?
|
| Referral and Consultation | 1 | 2012 | 383 | 0.340 |
Why?
|
| Heart Rate | 8 | 2011 | 568 | 0.340 |
Why?
|
| Polysomnography | 1 | 2010 | 92 | 0.340 |
Why?
|
| Cell Cycle | 3 | 2009 | 312 | 0.340 |
Why?
|
| Trans-Activators | 2 | 2008 | 237 | 0.340 |
Why?
|
| Cyclin E | 2 | 2008 | 19 | 0.340 |
Why?
|
| Health Care Costs | 1 | 2012 | 346 | 0.330 |
Why?
|
| Sleep Deprivation | 1 | 2009 | 81 | 0.330 |
Why?
|
| Thymidylate Synthase | 3 | 2006 | 42 | 0.330 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2008 | 2 | 0.330 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2007 | 99 | 0.330 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2021 | 18 | 0.330 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2009 | 216 | 0.330 |
Why?
|
| DNA-Binding Proteins | 2 | 2009 | 700 | 0.320 |
Why?
|
| Drug Administration Schedule | 16 | 1995 | 567 | 0.320 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 194 | 0.320 |
Why?
|
| Filgrastim | 3 | 2020 | 22 | 0.310 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 301 | 0.310 |
Why?
|
| Sarcoma | 3 | 2005 | 70 | 0.310 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2007 | 15 | 0.300 |
Why?
|
| Ki-67 Antigen | 1 | 2007 | 29 | 0.290 |
Why?
|
| Cyclosporins | 5 | 1988 | 10 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 772 | 0.290 |
Why?
|
| United States | 16 | 2021 | 7367 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 104 | 0.290 |
Why?
|
| Anxiety Disorders | 1 | 2010 | 426 | 0.280 |
Why?
|
| Gene Expression Regulation | 5 | 2010 | 1293 | 0.280 |
Why?
|
| Mutation | 2 | 2009 | 1213 | 0.280 |
Why?
|
| United States Department of Veterans Affairs | 4 | 2020 | 307 | 0.280 |
Why?
|
| Neoplasm Staging | 5 | 2011 | 800 | 0.280 |
Why?
|
| Biopsy | 4 | 2007 | 540 | 0.270 |
Why?
|
| Solar System | 1 | 2005 | 2 | 0.260 |
Why?
|
| Intestines | 1 | 2006 | 114 | 0.260 |
Why?
|
| Urinary Bladder Neoplasms | 7 | 1995 | 138 | 0.260 |
Why?
|
| Sunlight | 1 | 2005 | 59 | 0.260 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 710 | 0.260 |
Why?
|
| Progesterone | 3 | 2004 | 115 | 0.260 |
Why?
|
| Depressive Disorder, Major | 1 | 2010 | 439 | 0.250 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2005 | 44 | 0.250 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2005 | 48 | 0.250 |
Why?
|
| Treatment Outcome | 12 | 2020 | 7029 | 0.240 |
Why?
|
| Chronobiology Phenomena | 4 | 1999 | 4 | 0.240 |
Why?
|
| Photoperiod | 3 | 2009 | 11 | 0.240 |
Why?
|
| Rituximab | 2 | 2021 | 61 | 0.240 |
Why?
|
| Arrhythmia, Sinus | 3 | 1990 | 6 | 0.230 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 1987 | 41 | 0.220 |
Why?
|
| Lymphatic Metastasis | 7 | 2008 | 274 | 0.220 |
Why?
|
| Vaginal Smears | 3 | 2011 | 79 | 0.220 |
Why?
|
| Risk Assessment | 7 | 2020 | 2007 | 0.220 |
Why?
|
| Methylene Blue | 3 | 1988 | 16 | 0.220 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2005 | 300 | 0.210 |
Why?
|
| Incidence | 6 | 2019 | 1603 | 0.210 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2015 | 64 | 0.200 |
Why?
|
| Kidney Transplantation | 8 | 1992 | 839 | 0.200 |
Why?
|
| Risk Factors | 13 | 2012 | 5731 | 0.200 |
Why?
|
| Adenocarcinoma | 9 | 1990 | 475 | 0.200 |
Why?
|
| Kidney | 11 | 2001 | 945 | 0.190 |
Why?
|
| Estradiol | 1 | 2002 | 176 | 0.190 |
Why?
|
| Drug Industry | 2 | 2019 | 54 | 0.190 |
Why?
|
| RNA, Messenger | 4 | 2010 | 1664 | 0.190 |
Why?
|
| Prostatic Neoplasms | 6 | 2002 | 778 | 0.190 |
Why?
|
| Survival Analysis | 7 | 2010 | 714 | 0.180 |
Why?
|
| Polyethylene Glycols | 3 | 2020 | 149 | 0.180 |
Why?
|
| Models, Biological | 9 | 2012 | 981 | 0.180 |
Why?
|
| Disease Progression | 7 | 2009 | 1038 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 240 | 0.180 |
Why?
|
| Heparin | 5 | 1990 | 205 | 0.180 |
Why?
|
| Respiration | 4 | 1991 | 91 | 0.170 |
Why?
|
| Bevacizumab | 2 | 2020 | 34 | 0.170 |
Why?
|
| Mitotic Index | 3 | 2006 | 14 | 0.170 |
Why?
|
| Mitosis | 2 | 2006 | 76 | 0.170 |
Why?
|
| Recombinant Proteins | 5 | 2017 | 742 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 148 | 0.170 |
Why?
|
| Fertility | 1 | 1999 | 60 | 0.170 |
Why?
|
| Rectal Neoplasms | 1 | 2000 | 75 | 0.170 |
Why?
|
| Prognosis | 10 | 2021 | 2093 | 0.170 |
Why?
|
| Body Temperature | 5 | 1998 | 116 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 320 | 0.160 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 4848 | 0.160 |
Why?
|
| Colonic Polyps | 2 | 2009 | 63 | 0.160 |
Why?
|
| Cyclin D | 2 | 2008 | 12 | 0.160 |
Why?
|
| Rats | 20 | 2010 | 5300 | 0.160 |
Why?
|
| Cyclins | 2 | 2008 | 50 | 0.160 |
Why?
|
| Drug Costs | 1 | 2019 | 87 | 0.160 |
Why?
|
| Neoplasm Transplantation | 7 | 2009 | 160 | 0.160 |
Why?
|
| Papanicolaou Test | 2 | 2011 | 54 | 0.160 |
Why?
|
| Cost Savings | 1 | 2019 | 110 | 0.160 |
Why?
|
| Receptors, Erythropoietin | 2 | 2016 | 9 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 6 | 2009 | 2791 | 0.150 |
Why?
|
| Killer Cells, Natural | 2 | 1988 | 94 | 0.150 |
Why?
|
| Publishing | 1 | 2019 | 89 | 0.150 |
Why?
|
| Radiation-Protective Agents | 2 | 1988 | 16 | 0.150 |
Why?
|
| Mice, Mutant Strains | 2 | 2009 | 166 | 0.150 |
Why?
|
| Mice, Inbred Strains | 3 | 2006 | 181 | 0.150 |
Why?
|
| Natalizumab | 1 | 2017 | 6 | 0.150 |
Why?
|
| Receptors, Estrogen | 4 | 2012 | 142 | 0.150 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2005 | 52 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 434 | 0.140 |
Why?
|
| Transfection | 2 | 2009 | 782 | 0.140 |
Why?
|
| Endotoxins | 1 | 1997 | 76 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 62 | 0.140 |
Why?
|
| Shock, Septic | 1 | 1997 | 101 | 0.140 |
Why?
|
| Tumor Microenvironment | 2 | 2016 | 213 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2017 | 119 | 0.140 |
Why?
|
| Drugs, Generic | 1 | 2016 | 17 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2017 | 87 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 44 | 0.140 |
Why?
|
| Aging | 4 | 2010 | 911 | 0.130 |
Why?
|
| Transplantation, Homologous | 7 | 1992 | 242 | 0.130 |
Why?
|
| Oxidative Stress | 2 | 2010 | 718 | 0.130 |
Why?
|
| Vomiting | 2 | 1986 | 56 | 0.130 |
Why?
|
| Multiple Sclerosis | 1 | 2017 | 132 | 0.130 |
Why?
|
| Ketorolac | 2 | 2013 | 11 | 0.130 |
Why?
|
| Canada | 3 | 2019 | 267 | 0.130 |
Why?
|
| Lymph Nodes | 3 | 2006 | 258 | 0.130 |
Why?
|
| Netherlands | 2 | 2005 | 68 | 0.130 |
Why?
|
| Postmenopause | 2 | 2007 | 93 | 0.130 |
Why?
|
| Neutrophils | 2 | 2016 | 204 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2016 | 190 | 0.130 |
Why?
|
| Pyrimidines | 1 | 2016 | 178 | 0.130 |
Why?
|
| Eye Proteins | 2 | 2010 | 160 | 0.130 |
Why?
|
| Monitoring, Physiologic | 3 | 1985 | 219 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2009 | 1745 | 0.120 |
Why?
|
| Medicaid | 1 | 2017 | 302 | 0.120 |
Why?
|
| Lymphocytes | 4 | 2006 | 228 | 0.120 |
Why?
|
| Kidney Tubules | 1 | 1995 | 80 | 0.120 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 58 | 0.120 |
Why?
|
| Cell Separation | 1 | 2015 | 132 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 1998 | 375 | 0.120 |
Why?
|
| Retinal Pigment Epithelium | 3 | 2010 | 145 | 0.120 |
Why?
|
| Cryopreservation | 1 | 2015 | 103 | 0.120 |
Why?
|
| Ovariectomy | 2 | 2005 | 49 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 189 | 0.120 |
Why?
|
| Pigmentation Disorders | 3 | 1980 | 11 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1998 | 629 | 0.120 |
Why?
|
| Computer Simulation | 4 | 2013 | 706 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2011 | 622 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 331 | 0.110 |
Why?
|
| Liver | 3 | 2009 | 1118 | 0.110 |
Why?
|
| Melanoma | 1 | 2017 | 335 | 0.110 |
Why?
|
| Mercaptopurine | 2 | 1990 | 9 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2011 | 2800 | 0.110 |
Why?
|
| Disease Models, Animal | 5 | 2009 | 2550 | 0.110 |
Why?
|
| Infusions, Intravenous | 5 | 2000 | 334 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2016 | 384 | 0.110 |
Why?
|
| Heart Diseases | 2 | 1985 | 276 | 0.100 |
Why?
|
| Macrophages | 1 | 2016 | 647 | 0.100 |
Why?
|
| Forecasting | 3 | 2003 | 277 | 0.100 |
Why?
|
| Perioperative Care | 1 | 2013 | 100 | 0.100 |
Why?
|
| Cells, Cultured | 2 | 2015 | 2673 | 0.100 |
Why?
|
| Florida | 1 | 2012 | 221 | 0.100 |
Why?
|
| Sinoatrial Node | 1 | 1991 | 14 | 0.100 |
Why?
|
| Models, Theoretical | 2 | 2004 | 384 | 0.100 |
Why?
|
| Actigraphy | 1 | 2011 | 28 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2016 | 954 | 0.100 |
Why?
|
| Graft Survival | 3 | 1990 | 465 | 0.090 |
Why?
|
| CLOCK Proteins | 2 | 2008 | 7 | 0.090 |
Why?
|
| Vagus Nerve | 1 | 1991 | 90 | 0.090 |
Why?
|
| Heart Function Tests | 1 | 1991 | 33 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2016 | 902 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2010 | 931 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2010 | 125 | 0.090 |
Why?
|
| Colorectal Neoplasms | 3 | 2017 | 561 | 0.090 |
Why?
|
| Depression | 2 | 2009 | 943 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2010 | 340 | 0.090 |
Why?
|
| Pharmaceutical Preparations | 2 | 1992 | 101 | 0.090 |
Why?
|
| Mastectomy, Segmental | 1 | 2010 | 64 | 0.090 |
Why?
|
| Pancreas Transplantation | 2 | 1988 | 71 | 0.090 |
Why?
|
| Free Radicals | 2 | 1988 | 65 | 0.090 |
Why?
|
| Bone Marrow | 4 | 2000 | 168 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 2 | 2008 | 369 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2005 | 1040 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2010 | 284 | 0.090 |
Why?
|
| Renal Circulation | 1 | 1990 | 49 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 792 | 0.090 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2009 | 12 | 0.090 |
Why?
|
| Zidovudine | 1 | 1990 | 27 | 0.090 |
Why?
|
| Japan | 2 | 2020 | 68 | 0.090 |
Why?
|
| Tandem Repeat Sequences | 1 | 2009 | 13 | 0.090 |
Why?
|
| Eye | 1 | 2010 | 89 | 0.090 |
Why?
|
| DNA | 4 | 2005 | 597 | 0.090 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2009 | 14 | 0.090 |
Why?
|
| Probability | 3 | 2007 | 245 | 0.090 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1990 | 26 | 0.090 |
Why?
|
| Respiratory Mechanics | 1 | 1990 | 33 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 1992 | 514 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 1991 | 167 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 1046 | 0.090 |
Why?
|
| Europe | 2 | 2020 | 196 | 0.090 |
Why?
|
| Proteome | 1 | 2010 | 87 | 0.080 |
Why?
|
| Epoetin Alfa | 2 | 2021 | 23 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2010 | 183 | 0.080 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 2 | 2016 | 5 | 0.080 |
Why?
|
| Rats, Inbred Strains | 5 | 1989 | 532 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2007 | 329 | 0.080 |
Why?
|
| Retinal Diseases | 1 | 2009 | 40 | 0.080 |
Why?
|
| Epirubicin | 1 | 1988 | 4 | 0.080 |
Why?
|
| ARNTL Transcription Factors | 2 | 2006 | 6 | 0.080 |
Why?
|
| Histones | 1 | 2009 | 111 | 0.080 |
Why?
|
| Endostatins | 1 | 2009 | 11 | 0.080 |
Why?
|
| Fetal Heart | 1 | 1989 | 41 | 0.080 |
Why?
|
| Plasmacytoma | 1 | 1989 | 15 | 0.080 |
Why?
|
| Intestinal Polyps | 1 | 2008 | 15 | 0.080 |
Why?
|
| HCT116 Cells | 1 | 2008 | 63 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 1753 | 0.080 |
Why?
|
| Premedication | 1 | 2009 | 49 | 0.080 |
Why?
|
| Infusions, Intra-Arterial | 4 | 1990 | 27 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2012 | 335 | 0.080 |
Why?
|
| Fatigue | 1 | 2009 | 132 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2009 | 220 | 0.080 |
Why?
|
| DNA Damage | 1 | 2009 | 190 | 0.080 |
Why?
|
| Age Factors | 4 | 2004 | 1864 | 0.080 |
Why?
|
| Protein Stability | 1 | 2008 | 90 | 0.080 |
Why?
|
| Colonoscopy | 1 | 2009 | 156 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2006 | 58 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2011 | 431 | 0.080 |
Why?
|
| Fetus | 1 | 1989 | 157 | 0.080 |
Why?
|
| Retina | 1 | 2010 | 252 | 0.080 |
Why?
|
| Graft Rejection | 4 | 1990 | 458 | 0.080 |
Why?
|
| Sarcoma, Experimental | 1 | 1987 | 5 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2009 | 330 | 0.080 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 1987 | 12 | 0.080 |
Why?
|
| Phytoestrogens | 1 | 2007 | 5 | 0.080 |
Why?
|
| Humidity | 1 | 2007 | 12 | 0.080 |
Why?
|
| Radiation Tolerance | 1 | 1988 | 30 | 0.080 |
Why?
|
| Base Sequence | 1 | 2009 | 1015 | 0.080 |
Why?
|
| Colon | 1 | 2008 | 168 | 0.080 |
Why?
|
| RNA Interference | 1 | 2008 | 266 | 0.070 |
Why?
|
| Spleen | 1 | 1988 | 301 | 0.070 |
Why?
|
| Cell Survival | 3 | 2010 | 901 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2005 | 122 | 0.070 |
Why?
|
| Life Style | 1 | 2009 | 338 | 0.070 |
Why?
|
| Thrombocytopenia | 2 | 1978 | 122 | 0.070 |
Why?
|
| Genotype | 1 | 2009 | 786 | 0.070 |
Why?
|
| Recurrence | 5 | 2013 | 948 | 0.070 |
Why?
|
| Therapy, Computer-Assisted | 1 | 1987 | 57 | 0.070 |
Why?
|
| Inflammation | 2 | 2013 | 1030 | 0.070 |
Why?
|
| Gene Expression | 1 | 2009 | 770 | 0.070 |
Why?
|
| Random Allocation | 4 | 1990 | 442 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2009 | 297 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2010 | 597 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 207 | 0.070 |
Why?
|
| Interleukin-2 | 3 | 1996 | 133 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 191 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2009 | 1200 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1465 | 0.070 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 55 | 0.070 |
Why?
|
| Asparaginase | 2 | 1976 | 7 | 0.070 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 53 | 0.070 |
Why?
|
| Testis | 1 | 2006 | 37 | 0.070 |
Why?
|
| Germ-Line Mutation | 1 | 2006 | 43 | 0.070 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 1986 | 2 | 0.070 |
Why?
|
| Temperature | 1 | 2007 | 341 | 0.070 |
Why?
|
| Biometry | 1 | 2006 | 72 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 1990 | 445 | 0.070 |
Why?
|
| Apoptosis | 2 | 2010 | 1641 | 0.070 |
Why?
|
| Metoclopramide | 1 | 1985 | 21 | 0.070 |
Why?
|
| Ovary | 1 | 2006 | 99 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 6 | 1994 | 532 | 0.070 |
Why?
|
| Sex | 1 | 2005 | 7 | 0.070 |
Why?
|
| Infusions, Parenteral | 3 | 1993 | 47 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 195 | 0.070 |
Why?
|
| Methylcholanthrene | 1 | 2005 | 7 | 0.060 |
Why?
|
| Ovulation | 1 | 2005 | 10 | 0.060 |
Why?
|
| Nausea | 1 | 1985 | 47 | 0.060 |
Why?
|
| Combined Modality Therapy | 4 | 2012 | 951 | 0.060 |
Why?
|
| Capillary Permeability | 1 | 2005 | 69 | 0.060 |
Why?
|
| Motor Activity | 1 | 2008 | 621 | 0.060 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 1985 | 17 | 0.060 |
Why?
|
| Vitamin B 12 | 1 | 1985 | 21 | 0.060 |
Why?
|
| Reference Values | 2 | 2005 | 579 | 0.060 |
Why?
|
| Models, Animal | 1 | 2006 | 252 | 0.060 |
Why?
|
| HIV Infections | 2 | 1990 | 791 | 0.060 |
Why?
|
| Blood Vessels | 1 | 2005 | 102 | 0.060 |
Why?
|
| Dogs | 6 | 1992 | 490 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2011 | 1451 | 0.060 |
Why?
|
| Mammary Glands, Animal | 1 | 2005 | 71 | 0.060 |
Why?
|
| Pulse | 1 | 1984 | 23 | 0.060 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2004 | 38 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 1851 | 0.060 |
Why?
|
| Locomotion | 1 | 2005 | 135 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 3 | 1990 | 107 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2005 | 183 | 0.060 |
Why?
|
| Heart | 2 | 1991 | 850 | 0.060 |
Why?
|
| Kidney Diseases | 2 | 1984 | 307 | 0.060 |
Why?
|
| Biological Clocks | 1 | 1983 | 6 | 0.060 |
Why?
|
| Urine | 3 | 1988 | 47 | 0.060 |
Why?
|
| Menopause | 1 | 2004 | 47 | 0.060 |
Why?
|
| Exercise | 1 | 1990 | 658 | 0.060 |
Why?
|
| Vinblastine | 3 | 1988 | 40 | 0.060 |
Why?
|
| Heart Failure | 4 | 1991 | 1180 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2005 | 114 | 0.060 |
Why?
|
| Computational Biology | 1 | 2004 | 190 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 371 | 0.050 |
Why?
|
| Polyamines | 1 | 1983 | 79 | 0.050 |
Why?
|
| Health Status | 1 | 2005 | 429 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2006 | 403 | 0.050 |
Why?
|
| Leukocyte Count | 3 | 2000 | 94 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2003 | 289 | 0.050 |
Why?
|
| Body Weight | 3 | 1999 | 554 | 0.050 |
Why?
|
| Anxiety | 1 | 2005 | 422 | 0.050 |
Why?
|
| Hospitals | 1 | 2005 | 265 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1174 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2012 | 7277 | 0.050 |
Why?
|
| Blood Cell Count | 3 | 1995 | 35 | 0.050 |
Why?
|
| Age Distribution | 1 | 2003 | 320 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 30 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 25 | 0.050 |
Why?
|
| Lymphokines | 1 | 2001 | 49 | 0.050 |
Why?
|
| Growth Substances | 1 | 2001 | 77 | 0.050 |
Why?
|
| Photoreceptor Cells, Invertebrate | 1 | 2001 | 2 | 0.050 |
Why?
|
| Young Adult | 3 | 2020 | 5717 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2001 | 51 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2020 | 17 | 0.050 |
Why?
|
| Drosophila Proteins | 1 | 2001 | 44 | 0.050 |
Why?
|
| Drug Substitution | 1 | 2020 | 19 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2001 | 65 | 0.050 |
Why?
|
| Policy Making | 1 | 2020 | 51 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2001 | 64 | 0.050 |
Why?
|
| Escherichia coli | 3 | 1997 | 368 | 0.050 |
Why?
|
| Hematocrit | 3 | 1995 | 70 | 0.050 |
Why?
|
| Fibrosarcoma | 2 | 1999 | 21 | 0.050 |
Why?
|
| Drug Labeling | 1 | 2020 | 32 | 0.050 |
Why?
|
| Cyclophosphamide | 4 | 2005 | 129 | 0.040 |
Why?
|
| Rats, Inbred F344 | 5 | 1990 | 104 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2004 | 1553 | 0.040 |
Why?
|
| Prednisolone | 2 | 1990 | 23 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 767 | 0.040 |
Why?
|
| Mortality | 1 | 2001 | 163 | 0.040 |
Why?
|
| Lethal Dose 50 | 2 | 1994 | 13 | 0.040 |
Why?
|
| Litter Size | 1 | 1999 | 14 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2000 | 125 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1990 | 219 | 0.040 |
Why?
|
| Liver Neoplasms | 3 | 2007 | 334 | 0.040 |
Why?
|
| Adolescent | 3 | 2020 | 8912 | 0.040 |
Why?
|
| Pharmacovigilance | 1 | 2019 | 5 | 0.040 |
Why?
|
| Pregnancy | 2 | 1999 | 2334 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2004 | 3259 | 0.040 |
Why?
|
| Cattle | 2 | 2010 | 475 | 0.040 |
Why?
|
| Oxygen Consumption | 2 | 1991 | 258 | 0.040 |
Why?
|
| Hematologic Agents | 1 | 2019 | 11 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2019 | 42 | 0.040 |
Why?
|
| Receptors, Progesterone | 2 | 2012 | 57 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 1999 | 95 | 0.040 |
Why?
|
| Italy | 2 | 2010 | 36 | 0.040 |
Why?
|
| Hydrocortisone | 2 | 1998 | 291 | 0.040 |
Why?
|
| Patient Safety | 1 | 2020 | 202 | 0.040 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 117 | 0.040 |
Why?
|
| Drug Tolerance | 3 | 1990 | 80 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 319 | 0.040 |
Why?
|
| Leukopoiesis | 1 | 1998 | 1 | 0.040 |
Why?
|
| Thrombocytosis | 1 | 1978 | 7 | 0.040 |
Why?
|
| Erythropoiesis | 1 | 1998 | 24 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2001 | 682 | 0.040 |
Why?
|
| Prednisone | 2 | 1995 | 104 | 0.040 |
Why?
|
| Platelet Aggregation | 1 | 1978 | 127 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 392 | 0.040 |
Why?
|
| Drug Evaluation | 2 | 1990 | 47 | 0.040 |
Why?
|
| Proteomics | 2 | 2010 | 246 | 0.040 |
Why?
|
| Luteal Phase | 1 | 1998 | 25 | 0.040 |
Why?
|
| Skin | 1 | 2001 | 451 | 0.040 |
Why?
|
| Cell Line | 3 | 2010 | 1752 | 0.040 |
Why?
|
| Kinetics | 5 | 1986 | 1047 | 0.040 |
Why?
|
| Cell Lineage | 1 | 1998 | 146 | 0.040 |
Why?
|
| Darbepoetin alfa | 1 | 2017 | 13 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1997 | 32 | 0.040 |
Why?
|
| Remission Induction | 2 | 1988 | 111 | 0.040 |
Why?
|
| Veterans | 1 | 2005 | 904 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2016 | 21 | 0.040 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 15 | 0.040 |
Why?
|
| alpha-Fetoproteins | 2 | 1987 | 22 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 2 | 1987 | 17 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 158 | 0.040 |
Why?
|
| Adenine | 1 | 2016 | 46 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 3 | 1985 | 89 | 0.030 |
Why?
|
| Erwinia | 1 | 1976 | 1 | 0.030 |
Why?
|
| Drug Carriers | 2 | 2001 | 90 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1976 | 215 | 0.030 |
Why?
|
| Piperidines | 1 | 2016 | 123 | 0.030 |
Why?
|
| Carcinogens | 2 | 1974 | 86 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 2016 | 31 | 0.030 |
Why?
|
| Syndrome | 2 | 1995 | 255 | 0.030 |
Why?
|
| Leukemia | 1 | 1976 | 117 | 0.030 |
Why?
|
| Transplantation, Autologous | 3 | 1992 | 145 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 1995 | 57 | 0.030 |
Why?
|
| Digestive System | 2 | 1987 | 35 | 0.030 |
Why?
|
| Phenylhydrazines | 1 | 1995 | 4 | 0.030 |
Why?
|
| Stroke Volume | 2 | 1991 | 586 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 504 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 330 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 1995 | 114 | 0.030 |
Why?
|
| Consensus | 1 | 2016 | 211 | 0.030 |
Why?
|
| Life Tables | 1 | 1994 | 29 | 0.030 |
Why?
|
| Heart Transplantation | 2 | 1991 | 328 | 0.030 |
Why?
|
| Leukemia L1210 | 2 | 1985 | 14 | 0.030 |
Why?
|
| Magnesium | 1 | 1995 | 110 | 0.030 |
Why?
|
| Creatinine | 1 | 1995 | 243 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1994 | 47 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1994 | 109 | 0.030 |
Why?
|
| Nitrosourea Compounds | 1 | 1974 | 16 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 1994 | 186 | 0.030 |
Why?
|
| Lung Diseases, Interstitial | 1 | 1995 | 110 | 0.030 |
Why?
|
| History, 20th Century | 1 | 1995 | 248 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2010 | 483 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1420 | 0.030 |
Why?
|
| Sulfonic Acids | 1 | 1972 | 6 | 0.030 |
Why?
|
| Transplantation Immunology | 1 | 1972 | 11 | 0.030 |
Why?
|
| Methane | 1 | 1972 | 16 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2012 | 24 | 0.030 |
Why?
|
| Ribonucleosides | 1 | 1992 | 5 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 1993 | 84 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1993 | 223 | 0.030 |
Why?
|
| Drug Therapy | 1 | 1992 | 71 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2012 | 129 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 1991 | 17 | 0.020 |
Why?
|
| Prevalence | 2 | 2007 | 1619 | 0.020 |
Why?
|
| Rectum | 1 | 1991 | 62 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2004 | 1140 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2004 | 852 | 0.020 |
Why?
|
| Atropine | 1 | 1991 | 29 | 0.020 |
Why?
|
| Equipment Failure | 1 | 1991 | 112 | 0.020 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1991 | 14 | 0.020 |
Why?
|
| Biological Availability | 1 | 1991 | 79 | 0.020 |
Why?
|
| Isoproterenol | 1 | 1991 | 163 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 1986 | 137 | 0.020 |
Why?
|
| Immune System | 1 | 1991 | 63 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2010 | 92 | 0.020 |
Why?
|
| South Carolina | 1 | 2017 | 2752 | 0.020 |
Why?
|
| Diastole | 1 | 1991 | 161 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 272 | 0.020 |
Why?
|
| cis-trans-Isomerases | 1 | 2010 | 63 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2077 | 0.020 |
Why?
|
| Vimentin | 1 | 2010 | 47 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 84 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1988 | 381 | 0.020 |
Why?
|
| Local Area Networks | 1 | 1990 | 1 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1990 | 48 | 0.020 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1989 | 6 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 1989 | 23 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2010 | 85 | 0.020 |
Why?
|
| Computer Communication Networks | 1 | 1990 | 28 | 0.020 |
Why?
|
| Drug Implants | 1 | 1989 | 19 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 1980 | 106 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2010 | 167 | 0.020 |
Why?
|
| Los Angeles | 1 | 1989 | 30 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 168 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 234 | 0.020 |
Why?
|
| Caspases | 1 | 2010 | 194 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 280 | 0.020 |
Why?
|
| Hormones | 2 | 1983 | 42 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 284 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2009 | 36 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2009 | 26 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2009 | 40 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2009 | 40 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2010 | 305 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1990 | 193 | 0.020 |
Why?
|
| Fetal Monitoring | 1 | 1989 | 20 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 71 | 0.020 |
Why?
|
| Home Care Services | 1 | 1990 | 84 | 0.020 |
Why?
|
| Mathematics | 1 | 1989 | 83 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2009 | 114 | 0.020 |
Why?
|
| Estrogens | 2 | 2004 | 173 | 0.020 |
Why?
|
| Rhodopsin | 1 | 2009 | 135 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1988 | 22 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 1989 | 72 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 233 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 737 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 40 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2009 | 396 | 0.020 |
Why?
|
| Drug Therapy, Combination | 4 | 1984 | 649 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2010 | 195 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2008 | 21 | 0.020 |
Why?
|
| Injections, Subcutaneous | 2 | 1978 | 87 | 0.020 |
Why?
|
| Leucovorin | 1 | 2008 | 35 | 0.020 |
Why?
|
| Phytic Acid | 1 | 1988 | 4 | 0.020 |
Why?
|
| Antidiarrheals | 1 | 1988 | 3 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 1083 | 0.020 |
Why?
|
| Neoplastic Processes | 1 | 2007 | 2 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 3 | 1982 | 65 | 0.020 |
Why?
|
| Electrolytes | 1 | 1988 | 47 | 0.020 |
Why?
|
| Trace Elements | 1 | 1988 | 23 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 1988 | 39 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 1447 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 2 | 1979 | 17 | 0.020 |
Why?
|
| Down Syndrome | 1 | 2009 | 120 | 0.020 |
Why?
|
| Intestine, Small | 1 | 1988 | 89 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2008 | 124 | 0.020 |
Why?
|
| Blood Platelets | 2 | 1978 | 284 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1995 | 3705 | 0.020 |
Why?
|
| Digestive System Neoplasms | 1 | 1987 | 13 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 260 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1989 | 453 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 2006 | 12 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1988 | 411 | 0.020 |
Why?
|
| Axilla | 1 | 2006 | 36 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2006 | 28 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2006 | 53 | 0.020 |
Why?
|
| Lentinan | 1 | 2006 | 1 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 100 | 0.020 |
Why?
|
| Disulfiram | 1 | 1986 | 22 | 0.020 |
Why?
|
| Long-Term Care | 1 | 1986 | 53 | 0.020 |
Why?
|
| Magnetics | 1 | 2006 | 52 | 0.020 |
Why?
|
| SEER Program | 1 | 2006 | 153 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 2083 | 0.020 |
Why?
|
| Mitochondria | 1 | 2010 | 643 | 0.020 |
Why?
|
| Cobamides | 1 | 1985 | 1 | 0.020 |
Why?
|
| Methylmalonic Acid | 1 | 1985 | 6 | 0.020 |
Why?
|
| Weight Loss | 1 | 1988 | 319 | 0.020 |
Why?
|
| Homocysteine | 1 | 1985 | 28 | 0.020 |
Why?
|
| Tattooing | 1 | 2005 | 6 | 0.020 |
Why?
|
| Educational Status | 1 | 2006 | 273 | 0.020 |
Why?
|
| Prisons | 1 | 2005 | 18 | 0.020 |
Why?
|
| Methotrexate | 1 | 2005 | 91 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 1986 | 159 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 1985 | 150 | 0.020 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2005 | 30 | 0.020 |
Why?
|
| Keratins | 1 | 2004 | 48 | 0.010 |
Why?
|
| Compliance | 1 | 1984 | 26 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 955 | 0.010 |
Why?
|
| Microcomputers | 1 | 1984 | 32 | 0.010 |
Why?
|
| NAD | 1 | 1985 | 73 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1984 | 37 | 0.010 |
Why?
|
| Diabetic Neuropathies | 1 | 1984 | 33 | 0.010 |
Why?
|
| Diet | 1 | 1988 | 514 | 0.010 |
Why?
|
| Sex Factors | 4 | 1980 | 1266 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1984 | 120 | 0.010 |
Why?
|
| Putrescine | 1 | 1983 | 17 | 0.010 |
Why?
|
| Spermidine | 1 | 1983 | 21 | 0.010 |
Why?
|
| Neurons | 1 | 2009 | 881 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1988 | 1342 | 0.010 |
Why?
|
| Preventive Medicine | 1 | 1983 | 48 | 0.010 |
Why?
|
| Immunity | 1 | 1983 | 67 | 0.010 |
Why?
|
| Spermine | 1 | 1983 | 49 | 0.010 |
Why?
|
| Posture | 1 | 1984 | 107 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1985 | 567 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2005 | 205 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2006 | 448 | 0.010 |
Why?
|
| RNA | 1 | 1983 | 171 | 0.010 |
Why?
|
| Platinum | 1 | 1982 | 17 | 0.010 |
Why?
|
| Urination | 1 | 1982 | 19 | 0.010 |
Why?
|
| Cryptochromes | 1 | 2001 | 1 | 0.010 |
Why?
|
| Flavoproteins | 1 | 2001 | 4 | 0.010 |
Why?
|
| Micelles | 1 | 2001 | 43 | 0.010 |
Why?
|
| Remission, Spontaneous | 2 | 1979 | 25 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 282 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2001 | 294 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2001 | 167 | 0.010 |
Why?
|
| Testosterone | 2 | 1985 | 96 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1979 | 27 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1979 | 46 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1979 | 47 | 0.010 |
Why?
|
| Clone Cells | 1 | 1998 | 67 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 2279 | 0.010 |
Why?
|
| Semustine | 1 | 1977 | 2 | 0.010 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 1977 | 3 | 0.010 |
Why?
|
| Lomustine | 1 | 1977 | 10 | 0.010 |
Why?
|
| Progestins | 1 | 1977 | 19 | 0.010 |
Why?
|
| Androgens | 1 | 1977 | 41 | 0.010 |
Why?
|
| Diethylstilbestrol | 2 | 1974 | 45 | 0.010 |
Why?
|
| Potassium Iodide | 1 | 1996 | 1 | 0.010 |
Why?
|
| Acrylamide | 1 | 1996 | 3 | 0.010 |
Why?
|
| Drug Stability | 1 | 1996 | 71 | 0.010 |
Why?
|
| Acrylamides | 1 | 1996 | 12 | 0.010 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 1996 | 72 | 0.010 |
Why?
|
| Circular Dichroism | 1 | 1996 | 99 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 1996 | 136 | 0.010 |
Why?
|
| Vincristine | 1 | 1976 | 44 | 0.010 |
Why?
|
| Biological Assay | 1 | 1996 | 88 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 357 | 0.010 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 1995 | 12 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 1996 | 322 | 0.010 |
Why?
|
| Vital Capacity | 1 | 1995 | 43 | 0.010 |
Why?
|
| Adsorption | 1 | 1996 | 225 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 1995 | 87 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1977 | 215 | 0.010 |
Why?
|
| Cough | 1 | 1995 | 65 | 0.010 |
Why?
|
| Fever | 1 | 1995 | 96 | 0.010 |
Why?
|
| Dyspnea | 1 | 1995 | 87 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1996 | 397 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 1995 | 76 | 0.010 |
Why?
|
| Cyclohexanes | 1 | 1974 | 10 | 0.010 |
Why?
|
| Mesylates | 1 | 1974 | 5 | 0.010 |
Why?
|
| Acute Disease | 1 | 1976 | 658 | 0.010 |
Why?
|
| Inclusion Bodies, Viral | 1 | 1973 | 1 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1998 | 1034 | 0.010 |
Why?
|
| Medroxyprogesterone | 1 | 1973 | 3 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1973 | 351 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1973 | 43 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1973 | 132 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1973 | 93 | 0.010 |
Why?
|
| Esters | 1 | 1972 | 22 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 1972 | 22 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 1972 | 27 | 0.010 |
Why?
|
| Methods | 1 | 1972 | 156 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1972 | 20 | 0.010 |
Why?
|
| Species Specificity | 1 | 1973 | 303 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1972 | 144 | 0.010 |
Why?
|
| Pituitary Neoplasms | 1 | 1972 | 52 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1972 | 80 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1972 | 103 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 1972 | 68 | 0.010 |
Why?
|
| Adenoma | 1 | 1972 | 132 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1992 | 121 | 0.010 |
Why?
|
| Pharmacists | 1 | 1992 | 125 | 0.010 |
Why?
|
| Lung | 1 | 1995 | 849 | 0.010 |
Why?
|
| Pregnenediones | 1 | 1989 | 2 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1990 | 16 | 0.010 |
Why?
|
| Budesonide | 1 | 1989 | 10 | 0.010 |
Why?
|
| Carcinoma | 2 | 1984 | 215 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1989 | 618 | 0.000 |
Why?
|
| Dialysis | 1 | 1988 | 30 | 0.000 |
Why?
|
| Silicon | 1 | 1988 | 20 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1988 | 134 | 0.000 |
Why?
|
| Castration | 1 | 1985 | 13 | 0.000 |
Why?
|
| Child | 1 | 1976 | 6405 | 0.000 |
Why?
|
| Ureteral Neoplasms | 1 | 1984 | 8 | 0.000 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1988 | 529 | 0.000 |
Why?
|
| Acetylglucosaminidase | 1 | 1982 | 8 | 0.000 |
Why?
|
| Sodium Chloride | 1 | 1982 | 136 | 0.000 |
Why?
|
| Kidney Tubules, Proximal | 1 | 1982 | 81 | 0.000 |
Why?
|
| Aldosterone | 1 | 1980 | 51 | 0.000 |
Why?
|
| Corticosterone | 1 | 1980 | 51 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1980 | 420 | 0.000 |
Why?
|